PAXMAN publishes newsletter on positive study results in Japan and its expanded market clearance in Malaysia
Today, PAXMAN publishes the January 2019 issue of its newsletter aimed at shareholders, investors and other interested parties.
This issue highlights positive clinical study results with PAXMAN’s scalp cooling in Japan, the world’s second largest medical technology market, as well as a recently received market clearance in Malaysia. With a population of 30 million people, Malaysia has a promising growth potential for PAXMAN in 2019 and beyond.
To read the newsletter, and subscribe to receive upcoming issues, follow this link:
http://bit.ly/paxmanjanen
PAXMAN’s investor newsletter is published monthly as a part of the company’s effort to strengthen its market communication together with the IR communication agency Honeybadger. Every published issue of the newsletter is available on PAXMANs website for investors,www.paxman.se. The company encourages feedback and requests on topics for upcoming issues of the newsletter.
For further information, please contact:
Richard Paxman, CEO
Tel: +44 7968 020641
E-mail: richard@paxmanscalpcooling.com
www.paxmanscalpcooling.com
About PAXMAN
The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With more than 3,000 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN’s scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US)
The PAXMAN share is listed on Nasdaq First North. FNCA Sweden AB is the company’s Certified Adviser and can be contacted via info@fnca.se and +46 (0)8 528 003 99.